Business
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (&#x...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May\n\n\n\n VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company’s management and scientific teams will present at the following investor and scientific conferences in April and May:\n \n\n\n Osteoarthritis Research Society International World Congress April 24-27, 2025\n \n\n\n Dr. Phil Conaghan, a member of the Company’s OA Clinical Advisory Board, will be presenting a poster on the Company’s behalf at the Osteoarthritis Research Society International (“OARSI”) World Congress 2025, being held April 24-27, 2025 in Incheon (Seoul), South Korea.\n \n\n Poster Details\n \n\n Poster Title: EP-104IAR (extended-release intra-articular injection of fluticasone propionate) shows sustained pain response for subjects with moderate baseline pain and BMI less than 30 in SPRINGBOARD, a Phase 2, randomized, 24-week study of osteoarthritis of the knee.\n \n\n Date: Friday & Saturday, April 25-26, 2025\n \n Presentation Time: 3:30 – 4:15 PM KST\n \n Abstract ID: 4203902\n \n Poster Number: 635\n \n\n\n Digestive Disease Week Annual Meeting May 3-6, 2025\n \n\n\n The Company will be presenting data from the ongoing Phase 1b study of EP-104GI for the treatment of eosinophilic esophagitis (“EoE”) at the upcoming Digestive Disease Week (“DDW”) Annual Meeting 2025.\n \n\n Dr. Evan Dellon, Chair of the Company’s GI Clinical Advisory Board, will be presenting the poster on the Company’s ongoing Phase 1b/2a dose-escalation study of EP-104GI for EoE. Eupraxia's Chief Operating & Scientific Officer, Dr. Amanda Malone, will be presenting the poster on epidemiology of esophageal strictures.\n \n\n The meeting is being held in San Diego, CA, from May 3-6, 2025. Both posters will be presented on May 3, 2025.\n \n\n Poster Details\n \n\n Poster Title #1: Results from dose escalation from RESOLVE, an ongoing Phase 1b/2a dose-escalation study of EP-104GI ...